FDA Approves Bioequivalent of. Ampyra

[Marco]

The FDA has given final approval to Aurobindo Pharma Limited for dalfampridine extended-release tablets (10 mg). The agency’s Division of Bioequivalence determined the product is the bioequivalent of Amprya from Acorda Therapeutics, and it is indicated for the treatment of multiple sclerosis (MS).

http://www.pharmacytimes.com/product...iple-sclerosis

[pb909]

I read the link...and I'm not clear if this is intended to be a generic for the branded Amprya, or just another branded option?